BeOne Medicines (ONC) Other financing activities (2016 - 2026)

BeOne Medicines (ONC) has 11 years of Other financing activities data on file, last reported at $23.9 million in Q1 2026.

• On a quarterly basis, Other financing activities fell 62.32% year-over-year to $23.9 million in Q1 2026; TTM through Mar 2026 was $156.8 million, a 204.06% increase from a year earlier, with the FY2025 full-year figure at $196.3 million, up 6442.7% from the prior year.
• Other financing activities for Q1 2026 stood at $23.9 million, down from $196.3 million in the prior quarter.
• Over the last five years, Other financing activities for ONC reached as high as $196.3 million in Q4 2025 and fell as low as -$63.4 million in Q2 2025.
• Historically, Other financing activities has averaged $13.9 million across 5 years, with a median of $13.3 million in 2022.
• Across the five-year window, Other financing activities slumped 545.42% in 2023 and jumped 684.55% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$35.7 million in 2022, then tumbled by 46.74% to -$52.4 million in 2023, then surged by 35.86% to -$33.6 million in 2024, then soared by 684.55% to $196.3 million in 2025, then tumbled by 87.84% to $23.9 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $23.9 million in Q1 2026, $196.3 million in Q4 2025, and -$63.4 million in Q2 2025.